IL308465A - SARS-COV-2 polypeptides - Google Patents
SARS-COV-2 polypeptidesInfo
- Publication number
- IL308465A IL308465A IL308465A IL30846523A IL308465A IL 308465 A IL308465 A IL 308465A IL 308465 A IL308465 A IL 308465A IL 30846523 A IL30846523 A IL 30846523A IL 308465 A IL308465 A IL 308465A
- Authority
- IL
- Israel
- Prior art keywords
- cov
- sars
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190964P | 2021-05-20 | 2021-05-20 | |
| US202263341771P | 2022-05-13 | 2022-05-13 | |
| PCT/US2022/030068 WO2022246084A1 (en) | 2021-05-20 | 2022-05-19 | Sars-cov-2 polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308465A true IL308465A (en) | 2024-01-01 |
Family
ID=82321637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308465A IL308465A (en) | 2021-05-20 | 2022-05-19 | SARS-COV-2 polypeptides |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12653880B2 (enExample) |
| EP (1) | EP4294440A1 (enExample) |
| JP (1) | JP2024521098A (enExample) |
| KR (1) | KR20240012394A (enExample) |
| AU (1) | AU2022277697A1 (enExample) |
| BR (1) | BR112023024034A2 (enExample) |
| CA (1) | CA3212678A1 (enExample) |
| IL (1) | IL308465A (enExample) |
| MX (1) | MX2023013665A (enExample) |
| WO (1) | WO2022246084A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4547258A4 (en) * | 2022-06-28 | 2026-08-05 | Transcode Therapeutics Inc | Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy |
| CN115947801B (zh) * | 2022-12-29 | 2026-02-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用 |
| CN116143908B (zh) * | 2023-02-10 | 2026-07-10 | 武汉华美生物工程有限公司 | 一种针对VLPs类型抗原免疫产生高效价抗血清的方法 |
| WO2025231068A1 (en) * | 2024-04-30 | 2025-11-06 | The Regents Of The University Of Michigan | Compositions and methods for enhancing systemic and mucosal immune responses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013032421A2 (pt) | 2011-06-29 | 2017-01-17 | Immunotope Inc | método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue |
| WO2015130488A2 (en) | 2014-02-28 | 2015-09-03 | Immunotope, Inc. | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection |
| WO2015175361A1 (en) | 2014-05-13 | 2015-11-19 | Immunotope, Inc. | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development |
| EA201991377A1 (ru) | 2017-01-03 | 2020-01-21 | Эмерджекс Ваксинс Холдинг Лимитед | Композиции универсальной вакцины против гриппа |
| SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
| JP2021509400A (ja) | 2018-01-06 | 2021-03-25 | イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ | 複数のフラビウイルスの予防および治療を目的としたｍｈｃクラスｉ関連ペプチド |
| AU2019244435A1 (en) | 2018-03-29 | 2020-10-15 | Emergex Vaccines Holding Limited | Vaccine compositions |
| US20210283237A1 (en) | 2018-03-29 | 2021-09-16 | Emergex Vaccines Holding Limited | Vaccine compositions |
| CA3099643A1 (en) | 2018-05-18 | 2019-11-21 | Emergex Vaccines Holding Limited | Reverse peptide vaccine |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021204179A1 (en) * | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| EP4138876A1 (en) * | 2020-04-23 | 2023-03-01 | ISA Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
| GB202011652D0 (en) * | 2020-07-28 | 2020-09-09 | Univ Oxford Innovation Ltd | Polypeptide panels and uses thereof |
| US11191827B1 (en) * | 2020-12-09 | 2021-12-07 | Tevogen Bio Inc. | COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19 |
| EP4294435A1 (en) | 2021-02-16 | 2023-12-27 | Emergex Vaccines Holding Limited | Reverse peptides from coronavirus for immunogenic purposes |
| US20240269264A1 (en) | 2021-06-02 | 2024-08-15 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
-
2022
- 2022-05-19 BR BR112023024034A patent/BR112023024034A2/pt unknown
- 2022-05-19 WO PCT/US2022/030068 patent/WO2022246084A1/en not_active Ceased
- 2022-05-19 IL IL308465A patent/IL308465A/en unknown
- 2022-05-19 EP EP22735677.1A patent/EP4294440A1/en active Pending
- 2022-05-19 JP JP2023571758A patent/JP2024521098A/ja active Pending
- 2022-05-19 MX MX2023013665A patent/MX2023013665A/es unknown
- 2022-05-19 KR KR1020237039921A patent/KR20240012394A/ko active Pending
- 2022-05-19 AU AU2022277697A patent/AU2022277697A1/en not_active Abandoned
- 2022-05-19 US US17/748,715 patent/US12653880B2/en active Active
- 2022-05-19 CA CA3212678A patent/CA3212678A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022246084A1 (en) | 2022-11-24 |
| US12653880B2 (en) | 2026-06-16 |
| BR112023024034A2 (pt) | 2024-02-06 |
| MX2023013665A (es) | 2024-01-08 |
| JP2024521098A (ja) | 2024-05-28 |
| AU2022277697A1 (en) | 2024-01-04 |
| CA3212678A1 (en) | 2022-11-24 |
| US20220370601A1 (en) | 2022-11-24 |
| KR20240012394A (ko) | 2024-01-29 |
| EP4294440A1 (en) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289122A (en) | polypeptides | |
| IL289119A (en) | polypeptides | |
| GB202007441D0 (en) | Polypeptide | |
| GB202017649D0 (en) | Polypeptide | |
| GB201820556D0 (en) | Novel polypeptides | |
| IL299811A (en) | polypeptide | |
| IL317214A (en) | New polypeptides | |
| GB202019908D0 (en) | Cripr polypeptides | |
| GB202007532D0 (en) | Polypeptides | |
| SG11202102378WA (en) | Arginase1 polypeptides | |
| GB202019879D0 (en) | Polypeptide | |
| GB202315671D0 (en) | Polypeptides | |
| GB202219576D0 (en) | Polypeptides | |
| GB201913804D0 (en) | Fusion polypeptides | |
| GB202111640D0 (en) | Polypeptides | |
| GB202012736D0 (en) | Polypeptides | |
| GB202102758D0 (en) | Modified polypeptides | |
| GB201900621D0 (en) | Labelled polypeptides | |
| GB202312099D0 (en) | Polypeptides | |
| GB202211575D0 (en) | Polypeptides | |
| GB201911708D0 (en) | Polypeptides | |
| GB202119034D0 (en) | Polypeptide | |
| GB202105924D0 (en) | Polypeptide | |
| GB202103001D0 (en) | Polypeptide | |
| GB202100648D0 (en) | Polypeptide |